Adrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patients

2.50
Hdl Handle:
http://hdl.handle.net/2336/32952
Title:
Adrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patients
Authors:
Hardarson, A; Sigurdsson, G; Olafsdottir, E; Dallongeville, J; Berg, AL; Arnadottir, M
Citation:
J. Intern. Med. 2001, 250(6):530-4
Issue Date:
1-Dec-2001
Abstract:
OBJECTIVE: Recently, it was reported that treatment with adrenocorticotrophic hormone (ACTH) has a strong lipid-lowering effect in healthy individuals. The mechanism behind this has not been established. The aim of the present investigation was to study the effect of ACTH on the plasma lipoprotein pattern in patients treated with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. DESIGN: The ACTH treatment was given to 10 patients who were on long-term treatment with simvastatin 40 mg daily. ACTHI-24 was administered at the dose of 1 mg daily for four consecutive days. Blood samples for analyses of lipids, lipoproteins and apolipoproteins were collected before and after treatment. Second baseline was obtained 2 weeks after the end of treatment. RESULTS: The serum concentrations of cholesterol, triglycerides, low density lipoprotein (LDL) cholesterol, apolipoprotein B and lipoprotein(a) fell significantly by 16, 23, 23, 10 and 38%, respectively. The serum apolipoprotein E concentration increased significantly by 39%; the fraction that was not associated with apolipoprotein B increased by 47% whereas the fraction that was did not change significantly. There were no changes in the serum concentrations of high density lipoprotein (HDL) cholesterol and apolipoprotein AI. At the second baseline, the lipid variables had generally returned to previous levels. CONCLUSIONS: In patients on long-term simvastatin treatment, ACTH had marked lowering effects on the lipoproteins that contain apolipoprotein B. Moreover, the serum apolipoprotein E concentration increased significantly in response to ACTH treatment.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1046/j.1365-2796.2001.00919.x

Full metadata record

DC FieldValue Language
dc.contributor.authorHardarson, A-
dc.contributor.authorSigurdsson, G-
dc.contributor.authorOlafsdottir, E-
dc.contributor.authorDallongeville, J-
dc.contributor.authorBerg, AL-
dc.contributor.authorArnadottir, M-
dc.date.accessioned2008-07-24T09:12:52Z-
dc.date.available2008-07-24T09:12:52Z-
dc.date.issued2001-12-01-
dc.date.submitted2008-07-24-
dc.identifier.citationJ. Intern. Med. 2001, 250(6):530-4en
dc.identifier.issn0954-6820-
dc.identifier.pmid11902822-
dc.identifier.doi10.1046/j.1365-2796.2001.00919.x-
dc.identifier.urihttp://hdl.handle.net/2336/32952-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractOBJECTIVE: Recently, it was reported that treatment with adrenocorticotrophic hormone (ACTH) has a strong lipid-lowering effect in healthy individuals. The mechanism behind this has not been established. The aim of the present investigation was to study the effect of ACTH on the plasma lipoprotein pattern in patients treated with a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor. DESIGN: The ACTH treatment was given to 10 patients who were on long-term treatment with simvastatin 40 mg daily. ACTHI-24 was administered at the dose of 1 mg daily for four consecutive days. Blood samples for analyses of lipids, lipoproteins and apolipoproteins were collected before and after treatment. Second baseline was obtained 2 weeks after the end of treatment. RESULTS: The serum concentrations of cholesterol, triglycerides, low density lipoprotein (LDL) cholesterol, apolipoprotein B and lipoprotein(a) fell significantly by 16, 23, 23, 10 and 38%, respectively. The serum apolipoprotein E concentration increased significantly by 39%; the fraction that was not associated with apolipoprotein B increased by 47% whereas the fraction that was did not change significantly. There were no changes in the serum concentrations of high density lipoprotein (HDL) cholesterol and apolipoprotein AI. At the second baseline, the lipid variables had generally returned to previous levels. CONCLUSIONS: In patients on long-term simvastatin treatment, ACTH had marked lowering effects on the lipoproteins that contain apolipoprotein B. Moreover, the serum apolipoprotein E concentration increased significantly in response to ACTH treatment.en
dc.language.isoenen
dc.publisherBlackwell Scientific Publicationsen
dc.relation.urlhttp://dx.doi.org/10.1046/j.1365-2796.2001.00919.xen
dc.subject.meshAdrenocorticotropic Hormoneen
dc.subject.meshAgeden
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitorsen
dc.subject.meshHyperlipidemiasen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshSimvastatinen
dc.subject.meshStatistics, Nonparametricen
dc.subject.meshTreatment Outcomeen
dc.titleAdrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patientsen
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Landspitali University Hospital, Reykjavik, Iceland.en
dc.identifier.journalJournal of internal medicineen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.